Comparison between PSA density, free PSA percentage and PSA density in the transition zone in the detection of prostate cancer in patients with serum PSA between 4 and 10 ng/ml

Gregório, Émerson Pereira; Grando, João Paulo Souto; Saqueti, Eufanio Estefano; Almeida, Silvio Henrique Maia de; Moreira, Horácio Alvarenga; Rodrigues, Marco Aurélio Freitas

doi:10.1590/s1677-55382007000200004

Cited by 15 publications

(15 citation statements)

References 20 publications

(53 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There was a significant difference between the two groups. The above three indices can be used for differential diagnosis between PCA and BPH [7] . Compared to the TPSA, a higher sensitivity of the 3 indices can be found in diagnosing PCA, however, there was no obvious difference among the 3 indices.…”

Section: Resultsmentioning

confidence: 99%

The significance of PSA modified parameters (F/T)/PSAD for diagnosing prostatic cancer in the grey zone of 4∼10 ng/ml

Yan

Zhang

et al. 2007

Chin. J. Clin. Oncol.

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

The significance of PSA modified parameters (F/T)/PSAD for diagnosing prostatic cancer in the grey zone of 4∼10 ng/ml

Yan

Zhang

et al. 2007

Chin. J. Clin. Oncol.

View full text Add to dashboard Cite

“…The diagnostic rate reached 22.9% when coupled with biopsy by ultrasonic guidance, given f/t PSA ratios under 0.10 and PSA content in the range of 2.5-4.0 ng mL −1 [27,28]. In addition, PSA density and PSA volocity were other important potential references for prostate cancer diagnosis [29,30]. At present, diagnostic strategies to detect prostate cancer in China still mainly rely on digital rectal examination and imaging.…”

Section: No Current Test Can Replace Serum Psa For Mass Scree Ning Ofmentioning

confidence: 99%

Diagnostic strategies and the incidence of prostate cancer: reasons for the low reported incidence of prostate cancer in China

Zhang¹,

Wu²,

Guo³

et al. 2008

Asian J Androl

View full text Add to dashboard Cite

We have analysed the reasons for the low reported incidence of prostate cancer in China and argue for early diagnosis and treatment of this disease. According to the 2002 database of the International Agency for Research on Cancer (IARC), the age-standardized incidence of prostate cancer in China is 1.6/10 5 person years (PY), with a mortality rate of 1.0/10 5 PY and mortality-to-incidence rate ratio (MR/IR) = 0.63. The MR/IR ratio of prostate cancer in China was found to be higher than the average in Asia (MR/IR = 0.57) and much higher than that in North America (MR/IR = 0.13). These data indicate that in China most prostate cancers were in the advanced stages at the time of diagnosis, and that patients had a short survival time thereafter. In 2004, Stamey et al. reported a retrospective American study of prostate cancer for the years 1983-2003. It was shown that most cases of prostate cancer detected by prostate-specific antigen (PSA) screening were in the advanced stage at the start of this 20-year period. These early follow-up data are quite similar to the results obtained from mass PSA screening of elderly men in Changchun, China. However, after the American programmes for early diagnosis and treatment of prostate cancer were accepted, tumours were diagnosed at earlier stages. On the basis of these findings, mass screening should be performed in the whole of China using serum PSA to facilitate early diagnosis and treatment of prostate cancer.

show abstract

“…Since the dosing of serum PSA is accompanied by failure, variants of PSA measurements have been described in order to increase its accuracy: free/total PSA ratio, age-specific PSA, PSA density and PSA velocity (3). It was concluded that the combination of the PSA density, free PSA percentage and age are factors which contribute to high accuracy for PC detection (4). Despite the development of tools that help early diagnosis of organ-confined prostate cancer, up to 22% of newly diagnosed patients has been reported to have advanced or metastatic disease (5).…”

Section: Introductionmentioning

confidence: 99%

Do all patients with newly diagnosed prostate cancer need staging radionuclide bone scan? a retrospective study

et al. 2010

View full text Add to dashboard Cite

Purpose: Define a group of patients with newly diagnosed prostate cancer, whose risk of bone metastasis is low enough to omit a bone scan staging study. Materials and Methods: From 2003 to 2009, the medical records of patients who were newly diagnosed with prostate cancer were retrospectively reviewed. The data collected included: age, digital rectal examination, serum prostate specific antigen (PSA), Gleason score, clinical T stage, and bone isotope scan. Patients were divided into two groups according to the results of bone isotope scan; positive group and negative group. A univariate and multivariate binary logistic regression was used to analyze the results. Results: Of the 106 patients, 98 had a complete data collection and were entered into the study. The median age of the patients was 70.5 years and patients with a positive bone scan was 74 years, significantly higher than for patients with negative scans (69 years) (p = 0.02). Bone metastasis was detected in 39 cases (39.7%). In all patients with clinical T1-2 stage, a Gleason score of < 8 and PSA ≤ 20 ng/mL, the bone isotope scans were negative. In univariate analysis, PSA (> 20 ng/mL) and Gleason score (> 7) were independently predictive of positive bone scan, while clinical stage was not. Conclusion: Staging bone scans can be omitted in patients with a PSA level of ≤ 20 ng/mL, and Gleason score < 8. Our results suggest that by considering the Gleason score and PSA, a larger proportion of patients with prostate cancer could avoid a staging bone scan.

show abstract

Comparison between PSA density, free PSA percentage and PSA density in the transition zone in the detection of prostate cancer in patients with serum PSA between 4 and 10 ng/ml

Abstract: The determination of %FPSA and PSAD can allow a better discrimination between PCa and benign disease that the isolated use of PSA. The combination of PSADTZ, %FPSA, TZV and age promote a high accuracy for PCa detection.

Cited by 15 publications

References 20 publications

The significance of PSA modified parameters (F/T)/PSAD for diagnosing prostatic cancer in the grey zone of 4∼10 ng/ml

The significance of PSA modified parameters (F/T)/PSAD for diagnosing prostatic cancer in the grey zone of 4∼10 ng/ml

Diagnostic strategies and the incidence of prostate cancer: reasons for the low reported incidence of prostate cancer in China

Do all patients with newly diagnosed prostate cancer need staging radionuclide bone scan? a retrospective study

Contact Info

Product

Resources

About